The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Tanya Siddiqi, City of Hope Comprehensive Cancer Center, Duarte, US. In this video, Tanya Siddiqi discusses the TRANSCEND CLL 004 study.

Tanya Siddiqi describes findings from the TRANSCEND CLL 004 phase I/II study of a CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), in patients with relapsed or refractory chronic lymphocytic leukemia

TRANSCEND CLL 004 study